A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants

Disposition of [14C]-LY3437943 Following Subcutaneous Administration in Healthy Male Participants

The main purpose of this study is to is to look at how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it in healthy male participants. This study will involve a single dose of 14C radiolabeled LY3437943. his means that a radioactive tracer substance, C14, will be incorporated into the study drug to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine, feces and expired air.

The study will last up to approximately 15 weeks including the screening period of 28 days.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: [¹⁴C]-LY3437943

• Study Type: Interventional
• Enrollment (Actual): 7
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Wisconsin
    • Madison, Wisconsin, United States, 53704
      • Covance Clinical Research Unit

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Male participants who are overtly healthy as determined by medical evaluation
• Have a body mass index within the range 18.5 to 32.0 kilograms per meter squared (kg/m²)
• Have clinical laboratory test results within normal reference range for the population or investigative site, or results outside the normal reference range that are judged to be not clinically significant by the investigator. Participants with dyslipidemia may be included in the study, at the discretion of the investigator, as long as they fulfill other eligibility criteria
• Have venous access sufficient to allow for blood sampling as per the protocol
• Are willing to receive study treatment by SC injections
• Have a history of a minimum of 1 bowel movement per day
• Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria:

• Have a clinically significant abnormal blood pressure and/or pulse rate as determined by the investigator at screening or check-in
• Have significant history of or current cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the IP; or of interfering with the interpretation of data
• Have evidence of significant active neuropsychiatric disease, as determined by the investigator
• Show evidence of HIV infection and/or positive HIV antibodies, hepatitis C and/or positive hepatitis C antibody, hepatitis B and/or positive hepatitis B surface antigen
• Have a history of constipation or have had acute constipation within 3 weeks prior to check-in
• Have evidence of active renal disease (eg, diabetic renal disease, polycystic kidney disease) or an estimated creatinine clearance of less than 70 mL/minute, calculated using the Chronic Kidney Disease-Epidemiology equation
• Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) and/or elevation in serum amylase or lipase (greater than 1.5-fold the ULN) at screening
• Have used or plan to use over-the-counter or prescription medication, and/or dietary or herbal supplements (with the exception of vitamin supplements, acetaminophen and/or thyroid replacement therapy) within 14 days or 5 half-lives (whichever is longer) prior to dosing and for the duration of the study, including any medications that reduce GI motility, including, but not limited to, anticholinergics, antispasmodics, 5 hydroxytryptamine-3 receptor antagonists, dopamine antagonists, and opiates
• Have had exposure to significant radiation within 12 months prior to dosing (eg, serial x-ray or CT scans, barium meal, being employed in a job requiring radiation exposure monitoring)
• Have participated in any clinical trial involving a radiolabeled substance within the past 12 months

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: [¹⁴C]-LY3437943; Single dose of [¹⁴C]-LY3437943 administered subcutaneously (SC).	Drug: [¹⁴C]-LY3437943; Administered SC.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered	Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered	Predose up to 63 days post dose
Fecal Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered	Fecal Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered	Predose up to 63 days post dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC (0-∞)) of Total Radioactivity and [¹⁴C]-LY3437943	PK: AUC (0-∞) of Total Radioactivity and [¹⁴C]-LY3437943	Predose up to 63 days post dose
PK: Maximum Concentration (Cmax) of Total Radioactivity and [¹⁴C]-LY3437943	PK: Cmax of Total Radioactivity and [¹⁴C]-LY3437943	Predose up to 63 days post dose
Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable)	Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable)	Predose up to 63 days post dose
Total Number of Metabolites of LY3437943	Total Number of Metabolites of LY3437943	Predose up to 63 days post dose

Collaborators and Investigators

• Sponsor: Eli Lilly and Company
• Investigators: Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Study record dates

Study Major Dates

• Study Start (Actual): March 17, 2023
• Primary Completion (Actual): June 23, 2023
• Study Completion (Actual): June 23, 2023

Study Registration Dates

• First Submitted: February 24, 2023
• First Submitted That Met QC Criteria: February 24, 2023
• First Posted (Actual): March 7, 2023

Study Record Updates

• Last Update Posted (Actual): July 5, 2023
• Last Update Submitted That Met QC Criteria: July 1, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: ADME; Radioactive
• Other Study ID Numbers: 18217; J1I-MC-GZBG (Other Identifier: Eli Lilly and Company)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No